Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Acq. announced

Ikena Oncology, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/18/2023 D Form D - Notice of Exempt Offering of Securities:
08/18/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Acquisition/merger/asset purchase announced
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Agreement and Plan of Merger, by and among Ikena Oncology, Inc., Portsmouth Merger Sub I, Inc., Portsmouth Merger Sub II, LLC, Pionyr Immunotherapeutics, Inc. and Fortis Advisors LLC, as securityholder agent",
"Certificate of Designations of Series A Non-Voting Convertible Preferred Stock",
"Contingent Value Rights Agreement, by and between Ikena Oncology, Inc. and Computershare Trust Company N.A, as rights agent",
"Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction"
06/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/15/2023 8-K Investor presentation
Docs: "Underwriting Agreement, by and between Ikena Oncology, Inc. and Cowen and Company, LLC, as representative of the several underwriters named therein",
"Opinion of Goodwin Procter LLP",
"Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline",
"Ikena Oncology Inc. Corporate Presentation",
"Ikena Oncology Announces $40 Million Underwritten Offering"
05/15/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 8-K Quarterly results
03/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/14/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 SC 13G/A FMR LLC reports a 10.3% stake in IKENA ONCOLOGY INC
01/05/2023 4 Santillana Sergio L. (Chief Medical Officer) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 105,000 options to buy @ $2.62, valued at $275.1k
01/05/2023 4 Ecsedy Jeffrey (Chief Development Officer) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 105,000 options to buy @ $2.62, valued at $275.1k
01/05/2023 4 Zhang Xiaoyan Michelle (Chief Scientific Officer) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 105,000 options to buy @ $2.62, valued at $275.1k
01/05/2023 4 Manfredi Mark (President & CEO) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 220,000 options to buy @ $2.62, valued at $576.4k
01/05/2023 4 Marango Jotin (CFO & Head of Corp. Dev.) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 105,000 options to buy @ $2.62, valued at $275.1k
12/19/2022 4 Hughes Owen (Director) has filed a Form 4 on Ikena Oncology, Inc.
Txns: Granted 35,040 options to buy @ $2.62, valued at $91.8k
12/19/2022 3 Hughes Owen (Director) has filed a Form 3 on Ikena Oncology, Inc.
12/19/2022 8-K Quarterly results
11/28/2022 8-K Investor presentation
Docs: "Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update",
"Ikena Oncology, Inc. Corporate Presentation"
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/11/2022 SC 13G/A FMR LLC reports a 7% stake in IKENA ONCOLOGY INC
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/24/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/24/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy